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INTRODUCTION
Vascular access failure, the most frequent cause of morbid-
ity and hospitalization in patients undergoing hemodialysis, is
primarily due to vascular stenosis, which predisposes to throm-
bosis and subsequently leading to access obstruction. Neoin-
timal hyperplasia (NIH) is believed to be the predominant
cause of vascular stenosis of both the arteriovenous fistula and
the polytetrafluoroethylene (PTFE) graft (1, 2). The pathophys-
iology of NIH consists of an aberrant wound healing process
characterized by vascular smooth muscle cell (VSMC) migra-
tion, adherence, proliferation, and extracellular matrix deposi-
tion. The altered VSMC response is mediated in part by cyto-
kines and growth factors. Tumor necrosis factor- (TNF- )
stimulates the synthesis of other pro-inflammatory cytokines
and adhesion molecules; it has a chemotactic activity for
monocytes and stimulates migration and proliferation of
VSMC. Interleukin-10 (IL-10) exerts an anti-inflammatory
activity, which inhibits inflammatory cytokines such as TNF-
and inactivates inflammatory cells.
Inflammatory cytokine genes, or their promoter regions,
have single nucleotide polymorphisms that influence the rate
and magnitude of cytokine production. Many cytokine gene
polymorphisms have been reported to be associated with a pre-
disposition to develop a variety of inflammatory diseases (3, 4).
The transforming growth factor- 1 (TGF- 1) gene polymor-
phisms were reported to influence the risk for arteriovenous
fistula failure in patients undergoing hemodialysis (5). The
TNF- -308 gene polymorphism has been reported to be
associated with PTFE graft failure (3).
In this study, we examined the relationship between various
inflammatory markers and vascular access failure. We also eval-
uated the influence of TNF- and IL-10 genetic polymorp-
hisms on the development of vascular access failure.
MATERIALS AND METHODS
Patient population
From January to December 2005, 100 patients on mainte-
nance hemodialysis at the Korea University Anam Hospital
were selected for this cross-sectional study. Ninety-eight he-
althy individuals were recruited from the Medical Examination
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Interleukin-10 and Tumor Necrosis Factor- Polymorphisms in
Vascular Access Failure in Patients on Hemodialysis: Preliminary Data
in Korea
Neointimal hyperplasia causes vascular stenosis and subsequent thrombosis, which
result in vascular access failure in patients undergoing hemodialysis. Interleukin-10
(IL-10) and tumour necrosis factor- (TNF- ) are involved in this inflammatory pro-
cess. The aim of this study was to investigate the relationship between vascular ac-
cess failure and various inflammatory markers including the genetic polymorphisms
of IL-10 and TNF- . Seventy-five patients on hemodialysis with an arteriovenous fis-
tula in place or an artificial graft (18 with vascular access failure and 82 without fail-
ure) and 98 healthy individuals were genotyped for IL-10 and TNF- single nucleotide
polymorphisms. Clinical and laboratory data including serum IL-10 and TNF- lev-
els were compared. Stimulated IL-10 levels, from in vitro incubation of blood with
lipopolysaccharide, were also obtained and compared. Female gender, hypoproteine-
mia, and hypertriglyceridemia were associated with vascular access failure. The basal
TNF- level was significantly higher in patients with access failure. The distribution
of IL-10 and TNF- genotype did not differ among patients with or without access
failure. This study could not demonstrate a relationship between genetic polymor-
phisms and vascular access failure. However, an altered immune response and in-
flammation might contribute to vascular access failure.
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Informed consent was obtained in accordance with the guide-
lines set forth by the Declaration of Helsinki. Clinical infor-
mation, laboratory data, and history of vascular accesses of
study patients were assessed by a chart review. Vascular access
failure was defined as the need for any angioplastic or surgi-
cal intervention to correct poorly or non-functioning fistula
or graft.
Single nucleotide gene polymorphisms
Genomic DNA was prepared from peripheral blood mono-
nuclear cells from patients and from healthy controls using the
QIAmp DNA mini kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s specifications. Briefly, 1 mL of
whole blood was collected from a patient in a heparinized
tube, digested with proteinase-K, and submitted to a silica
gel QIAmp spin column. The blood column was washed
with appropriated buffers, and the total DNA was eluted
with 200  L of elution buffer. The total DNA recovered
from each sample was quantified and assessed for purity by
spectrophotometric analysis at 260 and 280 nm.
Cytokine genotyping for IL-10 (-1,082 G/A) and TNF-
(-308 G/A) was performed using the amplification refracto-
ry mutational system method (ARMS-PCR). Briefly, 0.1  g
of total DNA was amplified by PCR in a 10  L reaction mix-
ture containing 1×AS reaction buffer, 200  M deoxynucle-
otide triphosphate (dNTP), 1.5 mM MgCl2, 8.5% sucrose,
0.25 units ThermoprimePLUS DNA polymerase, 5  M specif-
ic primer mixture, and 1  M internal control primer mixture.
The primer sets for TNF- -308 PCR were generic primer 5′ -
TCTCGGTTTCTTCTCCATCG-3′ , primer G 5′ -ATAGG-
TTTTGAGGGGCATGG-3′ , and primer A 5′ -AATAGG-
TTTTGAGGGGCATGA-3′ . The primer sets for IL-10 -1,082
PCR are generic primer 5′ -CAGTGCCAACTGAGAATT-
TGG-3′ , primer G 5′ -CTACTAAGGCTTCTTTGGGAG-
3′ , and primer A 5′ -ACTACTAAGGCTTCTTTGGGAA-3′ .
Serum cytokine levels
A peripheral blood sample was obtained in a heparinized
bottle prior to hemodialysis and was divided into two wells.
One  g/mL of lipopolysaccharide (LPS E. coli, Sigma, St Louis,
U.S.A.) was added to one well. Samples and controls with-
out LPS were incubated at 37℃, 5% CO2 for 24 hr and spun
for 15 min, and the serum supernatant aliquots were stored
at -20℃ until analyzed. The serum IL-10 level was measur-
ed by the quantitative sandwich enzyme- linked immunosor-
bent assay (Quantikine, RD systems, Minneapolis, U.S.A.)
in accordance with the manufacturer’s instructions.
TNF- was studied on blood samples taken before hemo-
dialysis and allowed to clot; the samples were then spun for
15 min, and the serum supernatant aliquots were frozen at
-20℃. The serum TNF- level was measured by the same
method as above.
Statistics
Data management and statistical analysis were done using
the SPSS software. The  2-test was used to compare the geno-
type frequencies between healthy control and patient groups.
The nonparametric Mann-Whitney-U test was used to com-
pare continuous data including serum cytokine levels between
patients with or without vascular access failure. The Kruskal-
Wallis test was used for comparisons between healthy con-
trol and two patient groups. A p value <0.05 was considered
as significant.
RESULTS
Patient characteristics
Eighteen among 100 patients had vascular access failure.
Comparisons of baseline characteristics among the patients are
shown in Table 1. The patients on hemodialysis were much
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*A p value was less than 0.05 compared to the good access group; 
� A
p value was less than 0.05 compared to patients group. 
Patients
Healthy Good access Access failure
Number 98 82 18
Male (%) 50 (51) 43 (52) 5 (28)*
Age 42±13
� 59±14 57±12
Diabetes (%) 26 (32) 10 (56)
Hypertension (%) 74 (90) 16 (89)
Duration of hemodialysis (day) 1,841±1,077 1,480±1,836
Duration of vascular access (day) 1,769±1,131 1,101±1,594
Graft (%) 9 (11) 4 (22)*
Mean ejection fraction on
52 52 cardiac echo
Table 1. Comparisons of baseline characteristics among the pa-
tients
WBC, white blood cell; TIBC, total iron-binding capacity; BUN, blood urea
nitrogen; CRP, C-reactive protein.
Good access Access failure p value
Hemoglobin (g/dL) 10.0±1.2 9.8±1.2
WBC (10
3/mL) 6,244±1,790 6,054±1,933
Platelet (10
3/mL) 189±67 190±74
Protein (g/dL) 6.4±0.6 5.0±1.4 0.001
Cholesterol (mg/dL) 158±47 171±52 0.101
Triglyceride (mg/dL) 120±31 169±153 0.050
TIBC (mg/dL) 200±45 224±53 0.039
BUN (mg/dL) 67±24 57±20
Creatinine (mg/dL) 8.7±2.7 8.4±2.6
Uric acid (IU/L) 7.0±1.2 6.7±1.2
CRP (mg/dL) 7.9±11.4 8.0±9.6
Table 2. Comparisons of laboratory results between good access
and access failure groups older than the healthy control group. The proportion of female
and the proportion of PTFE graft were higher in the vascular
access failure group than the good functioning access group.
The prevalence of diabetes and hypertension, and duration
of hemodialysis and vascular access were not different between
patients with or without vascular access failure. Hypopro-
teinemia and hypertriglyceridemia were much more frequent
among the patients with vascular access failure (Table 2).
Distribution of cytokine genotype polymorphisms
The distribution of genotypes were 40% AA, 48% AG, 12
% GG for -1,082 IL-10, and 8% AA, 40% AG, 52% GG for
-308 TNF- . There was no difference in genotype frequen-
cies between the patients with vascular access failure and those
with good functioning access (Fig. 1).
Serum cytokine levels
Although the patients on hemodialysis produced a higher
level of LPS-stimulated IL-10 than healthy controls, no sig-
nificant differences were revealed among the patients with or
without access failure. Patients genotyped as A negative at
-1,082 IL-10 showed a higher level of LPS-stimulated IL-
10 level, GG>AG>AA (Fig. 2). There was no significant
difference in basal IL-10 levels.
Basal TNF- was much higher in the vascular access failure
group compared to the good functioning access group (Fig. 3).
Patients with AG at -308 TNF- exhibited a significantly
higher level of basal TNF- than GG or AA.
DISCUSSION
An aberrant wound healing process in response to chemical
or mechanical injury is believed to explain the pathophysiol-
ogy of NIH; VSMC proliferates and migrates into the intima
of vessels, where they induce intimal expansion via extracel-
lular matrix deposition. Although it is not clear whether the
fibroproliferative response occurs by way of inflammatory path-
ways or whether the inflammation is secondary to other driv-
ing mechanisms, several studies have suggested that inflam-
matory cytokines play a critical role in NIH. TNF- , a proxi-
mal inflammatory cytokine, stimulates the expression of adhe-
sion molecules and other pro-inflammatory cytokines includ-
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Fig. 1. Comparison between percentage frequencies of interleukin-
10 and tumour necrosis factor- genotypes in healthy controls, good
functioning access groups and access failure group.
Failure
Good
Healthy
Failure
Good
IL-10
0% 20% 40% 60% 80% 100%
TNF-
0% 20% 40% 60% 80% 100%
50 44 6
46 43 10
36 51
AA
13
6 50 44
9 37 54
AG GG
Fig. 2. Comparison between interleukin-10 single nucleotide poly-
morphisms in in vitro production of interleukin-10 protein in periph-
eral blood mononuclear cells after stimulating with lipopolysaccha-
ride.
Fig. 3. Comparison of the serum tumour necrosis factor- level
between the good functioning access group and the access fail-
ure group.
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0ing platelet-derived growth factor (PDGF) and TGF- 1,
which are important mediators of VSMC proliferation and
migration (6). The TNF- level was shown to increase for
several days prior to migration of VSMC into the intima, in
balloon-injured rat aorta; the TNF- antagonist-inhibited
coronary artery NIH in cholesterol-fed rabbits after cardiac
transplantation (7, 8). IL-10 exerts anti-inflammatory activ-
ities directed against the function of inflammatory cells, and
inhibits the production of inflammatory cytokines, such as
TNF- , IL-1, and IL-8. IL-10 was shown to interfere with
NIH, after balloon injury or stent implantation, in hyperc-
holesterolemic rabbits, and potently abrogates the prolifera-
tive response to atherogenic mitogens (8, 9).
The critical role of TNF- and IL-10 in NIH and the func-
tional relevance of the single nucleotide polymorphism sug-
gest a relationship between TNF- and IL-10 gene polymor-
phisms and vascular access failure in patients on hemodialy-
sis. Single nucleotide polymorphisms, located in the promoter
regions of the TNF- gene -308 and the IL-10 -1,082, have
been found to differentially affect binding of nuclear transcrip-
tion factors, transcriptional activity, and protein production
(4, 10-12). Expression of the A allele in -308 TNF- gene
results in increased genetic transcription and subsequent pro-
duction of TNF- compared to the normal production by
the genotype GG, and the presence of the A allele is associ-
ated with increased mortality in diabetic patients (12, 13).
The TNF- -308 gene polymorphism has been reported to
be associated with PTFE graft failure (3). However, based on
our results, the functionally relevant single nucleotide poly-
morphisms of the genes encoding TNF- and IL-10 did not
correlate with vascular access failure. These negative results
should not be interpreted as an argument against the impor-
tance of inflammatory responses elicited in vascular access
failure and the critical role of TNF- and IL-10 as regulators.
Instead, apparent lack of association may reflect the complex-
ity of interactions underlying the NIH and subsequent vascu-
lar stenosis, and may also largely be attributable to the inad-
equate sample size available for our study. In fact, previous
studies on the IL-10 -1,082 polymorphism have not always
revealed a relationship with inflammatory disease. A relation-
ship was not demonstrated in coronary artery restenosis after
angioplasty (14), rheumatoid arth- ritis and chronic hepatitis
(15, 16), development of cervical cancer (17), and prognosis
of lymphoma and breast cancer (18, 19).
In addition to the small sample size, there were other lim-
itations in this study. The patients examined in this study were
all Koreans, and different results may be obtained with pop-
ulations of other ethnic origins. The distribution of genetic
polymorphisms of the IL-10 -1,082 and TNF- -308 differ in
Caucasian populations (20). We did not compare the diameter
of the access vessels, an important factor for the development
of vascular access failure (21). Lastly, we did not measure the
stimulated TNF- level.
The results showed that female gender, hypoproteinemia, and
hypertriglyceridemia were associated with vascular access fail-
ure. This is in agreement with previous reports (21, 22). Fe-
male patients may have vessels of smaller diameter. Ernandez
et al. reported that female gender appears to be an independent
risk factor for early failure of AVF when adjusted for initial
artery diameter (21). Hypoproteinemia, as a result of inflam-
mation, might be related with vascular access failure. Inflam-
mation decreases the synthesis of protein in liver, and is asso-
ciated with a greater fractional catabolic rate and, when ext-
reme, increases the transfer of albumin out of the vascular
compartment. A vicious cascade of events ensues in which
inflammation induces anorexia and reduces the effective use
of dietary protein and energy intake and augments catabolism
of protein. De Marchi et al. reported that a high total choles-
terol/HDL cholesterol ratio and hypertriglyceridemia are
powerful risk indicators for fistula obstruction of patients on
hemodialysis (22).
In conclusion, this cross-sectional study did not reveal a rela-
tionship between vascular access failure and single nucleotide
polymorphisms of IL-10 -1,082 and TNF- -308. However,
female gender, hypoproteinemia, and hypertriglyceridemia
could be risk factors for the development of access failure, and
the imbalance of cytokine networks including TNF- from
uremia could have influenced the development of access fail-
ure. Further prospective studies involving a large study popu-
lation should follow to inrolentify factors that are useful in
detection of risk factors for access failure to improve the man-
agement of patients on hemodialysis.
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